Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

acromegaly

This page shows the latest acromegaly news and features for those working in and with pharma, biotech and healthcare.

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA. Signifor LAR shows superior efficiency to older treatments. ... Physicians now have a new acromegaly therapy that provides an enhanced mechanism to address elevated hormone levels," she added.

Latest news

  • FDA approves Ipsen drug to treat rare tumours FDA approves Ipsen drug to treat rare tumours

    Somatuline Depot is already available in the US as a treatment for a condition known as acromegaly where patients overproduce a growth hormone. .

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    Novartis gets EU nod for rare disease drug Signifor. Long-acting formulation of drug approved for growth disorder acromegaly. ... This first approval of Signifor in acromegaly marks a much needed advance in the treatment of this rare disease.".

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    A phase III trial of Novartis' somatostatin analogue Signifor has suggested it could be effective for the growth hormone disorder acromegaly. ... may offer benefit for acromegaly patients whose disease is not fully controlled on their current therapy.".

  • Shining a light on orphan medicines Shining a light on orphan medicines

    Patient registries such as the Pfizer International Growth Study (KIGS), Pfizer International Metabolic Study (KIMS), Pfizer's ACROSTUDY database for patients with acromegaly, and Shire HGT's Fabry Outcome Survey (FOS)

  • Roche licenses Chiasma’s acromegaly drug in $595m deal Roche licenses Chiasma’s acromegaly drug in $595m deal

    Roche licenses Chiasma’ s acromegaly drug in $595m deal. Alternative to injection for hormonal disorder. ... Our oral octreotide has the potential to improve the quality of life of acromegaly patients," says Chiasma.

More from news
Approximately 4 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    the growth hormone condition acromegaly - accounting for over half of that.

  • Charting a course for expansion Charting a course for expansion

    The drug treats the hormonal disorder acromegaly and neuroendocrine tumours (NETs), a rare form of cancer.

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    Meanwhile, Chiasma remains committed to the development of an oral form of the peptide drug octreotide - a growth hormone inhibitor used to treat acromegaly - despite Roche's decision to hand back

  • Pharma deals in May 2015 Pharma deals in May 2015

    Staying with rare diseases, Cortendo closed a deal with Antisense Therapeutics for ATL 1103 in acromegaly. ... 116. Antisense/ Cortendo. Licence agreement. To develop and market ATL 1103 [P2 ready] in endocrine disorders including acromegaly.

  • Pharma deals during August 2014 Pharma deals during August 2014

    Not all planned alliances however run a smooth course as was the case with the Chiasma/ Roche $600m commercial agreement for Octreolin, the orally acting acromegaly drug.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Kirsti Gjellan swaps Pfizer for Sobi Kirsti Gjellan swaps Pfizer for Sobi

    The site opened in 2009 to produce the active ingredients for growth hormone Genotropin (somatropin) and the acromegaly treatment Somavert (pegvisomant).

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Quick links

Infographics

Multimedia